Largactil (Chlorpromazine Hydrochloride)

Chlorpromazine hydrochloride blocks dopamine D2 receptors, reducing dopaminergic activity that contributes to psychosis. It also antagonizes histamine, muscarinic, and alpha‑adrenergic receptors, which adds sedative, anticholinergic, and blood‑pressure‑lowering properties, collectively helping to calm severe psychiatric symptoms.

The specific dose of Largactil is determined by the prescribing clinician based on the individual’s clinical condition, severity of symptoms, and response to therapy. Healthcare professionals adjust the amount and frequency to achieve optimal therapeutic benefit while minimizing adverse effects.

Safety of Largactil in pregnancy or while nursing has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To request Largactil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Largactil belongs to the phenothiazine class, a typical antipsychotic, and differs from atypical agents by primarily blocking dopamine D2 receptors. It often provides rapid sedation, which can be advantageous in acute agitation, but may have a higher incidence of extrapyramidal side effects compared with newer atypical antipsychotics.

Largactil should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light to maintain stability. Do not freeze or expose it to extreme temperatures.

Largactil is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and infusion rate are selected by the treating clinician according to the clinical situation and patient tolerance.

Serious risks include extrapyramidal symptoms such as severe muscle rigidity, neuroleptic malignant syndrome, tardive dyskinesia, significant hypotension, agranulocytosis, and cardiac arrhythmias. Prompt medical attention is required if any of these events are suspected.

Largactil is contraindicated in patients with known hypersensitivity to chlorpromazine or any phenothiazine component, those with severe cardiovascular disease that could be worsened by hypotension, and individuals with a history of malignant hyperthermia. Caution is also advised for patients with existing neurological disorders.